Biogen Inc.
BIIB Healthcare Drug Manufacturers General
Biogen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.9 billion, up 2.22% from fiscal 2024. In the quarter to June 2026, revenue grew 3.42%, EPS fell 84.8%, free cash flow grew 103.3% and total debt rose 16.0%, each against the same quarter a year earlier. Member of the S&P 500; insiders bought in the last twelve months.
Follow BIIB
Biogen Inc. (BIIB) Net income
Biogen Inc.'s net income for fiscal 2025 was $1.3B, down 20.8% from $1.6B in fiscal 2024. Over the twelve months to 30 June 2026 it was $834.6M. Over the past ten years it has ranged from $1.2B (fiscal 2023) to $5.9B (fiscal 2019); the current reading is higher than 18% of that period. Biogen Inc. ranks 13th of 21 Drug Manufacturers General companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $1.3B | (20.79%) |
| FY2024 | $1.6B | 40.53% |
| FY2023 | $1.2B | (60.78%) |
| FY2022 | $3.0B | 71.43% |
| FY2021 | $1.7B | (57.45%) |
| FY2020 | $4.1B | (31.04%) |
| FY2019 | $5.9B | 31.62% |
| FY2018 | $4.5B | 67.56% |
| FY2017 | $2.7B | (27.75%) |
| FY2016 | $3.7B | 2.85% |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | $97.5M | (69.48%) |
| Mar 2026 | $319.5M | — |
| Dec 2025 | −$48.9M | — |
| Sep 2025 | $466.5M | (26.51%) |
| 42 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| NVO Novo Nordisk A/S compare | $17.9B |
| AZN AstraZeneca PLC compare | $12.6B |
| BMY Bristol Myers Squibb Company compare | $9.3B |
| AMGN Amgen Inc. compare | $8.7B |
| GSK GSK PLC Sponsored ADR compare | $6.9B |
| SNY Sanofi compare | $4.5B |
| PFE Pfizer Inc. compare | $4.4B |
| BIIB Biogen Inc. | $834.6M |
| GILD Gilead Sciences, Inc. compare | −$3.2B |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on BIIB
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement